Progressive genetic conditions aren’t always a death sentence, but oftentimes, they create unwanted challenges for those who suffer from them. That’s why so many in the neuroscience community are celebrating the approval of a new drug called Koselugo, which treats neurofibromatosis type 1, or NF1. The disease, which is generally diagnosed in young children, can now be controlled from an early age, without invasive treatments like chemo or surgery.
So, what is the new treatment option for neurofibromatosis?
“Children living with NF1 [or] PN may face physical challenges and significant disruption to their daily lives, and early intervention is essential as tumor growth is often progressive and rapid, especially in the first decade of life,” stated Li Qingfeng, Vice President of Shanghai Ninth People’s Hospital, in a press release. “The approval of Koselugo in China has the potential to change the treatment trajectory of this debilitating genetic condition.”
